Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Reverse Triple Negative Immune Resistant Breast Cancer

Next Previous
X
Search
Trial Profile

Reverse Triple Negative Immune Resistant Breast Cancer

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 13 Feb 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Camrelizumab (Primary) ; Choline (Primary) ; Efavirenz (Primary) ; Sodium cromoglicate (Primary)
  • Indications Advanced breast cancer; Triple negative breast cancer
  • Focus Pharmacodynamics; Therapeutic Use
  • Acronyms Renaissance

    • Most Recent Events

    • 29 Sep 2022 According to ClinicalTrials.gov record, protocol has been amended to increase patient number from 20 to 30, treatment arm changed from 2 to 3
    • 29 Sep 2022 Planned number of patients changed from 20 to 30.
    • 01 Apr 2022 Planned initiation date changed from 15 Oct 2021 to 1 Apr 2022.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top